ABSTRACT.Purpose: To investigate visual field loss in patients on long-term treatment with the antiepileptic drug vigabatrin, recently reported to cause visual disturbances. Methods: Eighteen patients taking vigabatrin for 0.5-9.5 years were examined with automated perimetry up to 60ae from fixation using the Humphrey Field Analyser. Five patients with epilepsy receiving other medications served as controls. Patients found to have a visual field defect underwent ophthalmologic examination. Results: Among the 18 patients in the vigabatrin group, visual field defects categorised as mild were revealed in 6 right eyes (33%) and 8 left eyes (44.4%), while defects categorised as severe were found in 9 right eyes (50%) and 8 left eyes (44.4%). The majority of the defects (66.7% in the right eye) were peripheral constriction with nasal predominance. The location of the defects was confirmed in 8 patients also tested with Kowa AP340 perimetry. Conclusion: According to our results, visual field defects among the patients on vigabatrin therapy may occur more frequently than previously recognised. V igabatrin (VGB) is an effective antiepileptic drug acting as a relatively specific irreversible inhibitor of gammaaminobutyric acid (GABA) transaminase. Inhibition of this enzyme produces an elevation of GABA concentrations in the brain associated with anticonvulsant effect (Mattson et al. 1994;Petroff et al. 1996aPetroff et al. , 1996bAvanzini et al. 1997). No abnormalities in central nervous system conduction related to VGB treatment in humans have been observed (Mauguière et al. 1997). In the vertebrate retina, GABA is one of the most important inhibitory transmitters (Berman 1991).Currently, VGB has been used for more than 12 years for treatment of partial seizures (Marson et al. 1997). It was found to be less effective, but better tolerated than carbamazepine, which is the first-choice drug for the treatment of partial epilepsies (Chadwick 1999). Recently, several reports have documented persistent visual field defects in patients with long-term use of VGB, either as monotherapy or concurrently with other antiepileptic drugs (Blackwell et al. 1997;Eke et al. 1997;Harding 1997;Wilson & Brodie 1997;Wong et al. 1997;Williams & Brennan 1997;Krauss et al. 1998;Ruether et al. 1998;Daneshvar et al. 1999;Kälviäinen et al. 1999;Wilton et al. 1999). According to these, VGB seems to increase the risk of a unique and specific pattern of bilateral, mainly asymptomatic visual field constriction (Kälviäin-en et al. 1999). The incidence of these visual field defects was recently found to be substantially higher than previously assumed. A frequency as high as 40% (9% mild, 31% severe) among patients on VGB monotherapy has been reported (Kälviäinen et al. 1999). Any clear risk factors regarding age, duration of the treatment, the dosage or the cumulative amount of VBG consumed during the treatment were not found (Kälviäinen et al. 1999;Daneshvar et al. 1999). Unfortunately, irreversible visual field defects after cessation of the VGB therapy...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.